Lexaria Bioscience Corp.: Exhibit 10.9 - Filed by newsfilecorp.com






THIS JOINT VENTURE AGREEMENT made the 6th day
of April, 2017.

BETWEEN 


	NEUTRISCI INTERNATIONAL CORP., with an
      address at Suite 1600 – 609 Granville Street Vancouver, British Columbia
      V7Y 1C3 
	  
	("NeutriSci") 



AND: 


	LEXARIA BIOSCIENCE CORP., with an address at
      156 Valleyview Road, Kelowna, British Columbia V1X 3M4 
	  
	("Lexaria" and together with NeutriSci, the
      "Parties") 



WHEREAS: 

A.      The Parties entered into a
memorandum of understanding dated November 9, 2016 setting forth the basic terms
of a proposed joint venture agreement; 

B.      NeutriSci and Lexaria each
wish to incorporate a jointly owned corporation (“Newco”) under the laws
of British Columbia for the purpose of developing and selling a line of products
that incorporate Lexaria’s technology for enhancing palatability and
bioavailability of beneficial molecules including, but not limited to,
cannabinoids, in NeutriSci’s existing and pipeline product formats (the
"Business");

C.      The Parties are entering into
this Agreement to set out the terms and conditions by which NeutriSci and
Lexaria will each own a 50% interest in Newco and the Business. 

NOW THEREFORE THIS AGREEMENT
WITNESSETH that in consideration of the premises and the mutual covenants
and agreements hereinafter set forth, the parties hereto agree each with the
other as follows: 




1.         DEFINITIONS
AND SCHEDULES 

1.01      In this Agreement, unless
the context otherwise requires, the following terms will have the following
meanings: 

“Closing” or “Closing Date” has the meaning
assigned thereto in Section 2.02 of this Agreement. 

"Effective Date" has the meaning assigned thereto in
Section 2.02 of this Agreement. 

“Equity Financing” has the meaning assigned thereto in
Section 4.11 of this Agreement.

"Governmental Authorities" means any governments,
whether federal, provincial, or municipal, and any branch, department or
ministry thereof, or any governmental agency, authority, board, tribunal or
commission of any kind whatsoever. 

“Initial Contribution” has the meaning assigned thereto
in Section 2.01 of this Agreement. 

“Jointly Owned IP” has the meaning assigned thereto in
Section 6.05 of this Agreement. 

"Joint Venture" has the meaning assigned thereto in
Section 2.06 of this Agreement.

"Joint Venture Assets" mean and any future assets
purchased by or created on behalf of Newco and the Business and all other
property, whether real, personal, or intellectual which is owned, leased, held,
developed, constructed or acquired for the Business by or on behalf of the
Parties.

"Law" or "Laws" means all applicable domestic and
foreign national, federal, state and local Laws (statutory or common), rules,
ordinances, regulations, grants, concessions, franchises, licenses, orders,
directives, judgments, decrees, and other governmental restrictions, including
permits and other similar requirements, whether legislative, municipal,
administrative or judicial in nature. 

“Lexaria IP” has the meaning assigned thereto in Section
6.01 of this Agreement.

“Lexaria New IP” has the meaning assigned thereto in
Section 6.04 of this Agreement.

"Liabilities" means: (i) any and all penalties, costs,
losses, damages, judgments, settlements, disbursements, expenses, fees,
obligations, debts, duties, judgments and other liabilities howsoever
characterized, whether known or unknown, accrued or unaccrued, actual,
contingent or otherwise, and any and all actions, claims, contests, suits,
proceedings, demands and other judicial or administrative actions seeking to
impose any of the foregoing; and (ii) environmental liabilities. 

"MOU" means the memorandum of understanding dated
November 9, 2016 entered into between NeutriSci and Lexaria.

“NeutriSci IP” has the meaning assigned thereto in
Section 6.02 of this Agreement. 

“NeutriSci New IP” has the meaning assigned thereto in
Section 6.03 of this Agreement. 

"Net Profits" means income available for distribution to
the Parties after deducting all expenses incurred by the Business as determined
by quarterly financial statements of the Business, and specifically excludes
non-Business activities of the Parties. 




“Newco Improvements” has the meaning assigned thereto in
Section 6.06 of this Agreement. 

"Operations" means all activities carried out by the
officers and directors of Newco in respect of the Business.

"Ownership Interest" means all the right, title
and interest of a Party in and to the Joint Venture, the Joint Venture Assets
and accrued interest thereon and the Party's interest in and to this Agreement.


"Person" means any individual, firm, partnership, joint
venture, trust, corporation, limited liability company, unincorporated
organization, estate or other business entity. 

"Parties" means the parties to this Agreement and their
respective successors and permitted assigns which become parties pursuant to
this Agreement. 

“Revenue Interests” has the meaning assigned thereto in
Section 2.05 of this Agreement. 

"Tax" and "Taxes" shall mean any or all Canadian
federal, provincial, local or foreign (i.e. non-Canadian) income, gross
receipts, real property gains, goods and services, license, payroll, employment,
excise, severance, stamp, occupation, premium, windfall profits, environmental,
customs duties, capital stock, franchise, profits, withholding, social security
(or similar), unemployment, disability, real property, personal property, sales,
use, transfer, registration, value added, alternative or add-on minimum, or
other taxes, levies, governmental charges or assessments of any kind whatsoever,
including, without limitation, any estimated tax payments, interest, penalties
or other additions thereto, whether or not disputed. 

1.02      The following is a list of
schedules to this Agreement: 

             
Schedule "A" – Form of Articles 

INITIAL CONTRIBUTIONS & INTERESTS 

2.01      The Parties will contribute
the following as initial contributions for the purpose of acquiring an ownership
interest in Newco and to provide the necessary funding of initial operating
costs of the Business for the first three (3) to six (6) months: 

	 	(a) 	
      NeutriSci, as its initial contribution, will deposit
      CDN$25,000 into Newco’s bank account or other such account as the parties
      may agree.

	 	 	 
	 	(b) 	
      Lexaria, as its initial contribution, will deposit
      CDN$25,000 into Newco’s bank account or other such account as the parties
      may agree.



(together, the “Initial
Contribution”) 




2.02      Upon completion of the
Initial Contribution by each party (the “Closing” or “Closing
Date”) and the completion of the incorporation of Newco (together, with the
Closing Date, the “Effective Date”), the Parties ownership interests in
Newco and the Business will be the following: 


	 	NeutriSci 	- 	50% 
	 	Lexaria 	- 	50% 



2.03      Upon the Effective Date, and
except for the President’s Salary (as defined section 4.10) the Parties shall
bear the costs arising under this Agreement and the operation of the Business as
to the following: 


	 	NeutriSci 	- 	50% 
	 	Lexaria 	- 	50% 



2.04      Upon the Effective Date, and
except for the President’s Salary, the Parties shall have the following
liability for all things that are not operating costs arising under this
Agreement and the operation of the Business as to the following:


	 	NeutriSci 	- 	50% 
	 	Lexaria 	- 	50% 



2.05      Upon the Effective Date, the
Parties shall receive all revenues and profits derived from the operation of the
Business as to the following (the “Revenue Interests”): 


	 	NeutriSci 	- 	50% 
	 	Lexaria 	- 	50% 



2.06      On Closing, NeutriSci and
Lexaria shall be deemed to have formed a joint venture for operation and further
development of the Business of Newco (the "Joint Venture"). 

3.        
 REPRESENTATIONS, WARRANTIES AND COVENANTS 

3.01      Each of NeutriSci and
Lexaria represents and warrants to the other as follows: 

	 	(a) 	
      It is duly incorporated and is in good standing as to the
      filing of annual returns under the laws of the jurisdiction of its
      incorporation.

	 	 	 
	 	(b) 	
      It has the corporate or other power to enter into this
      Agreement.

	 	 	 
	 	(c) 	
      All necessary and requisite corporate proceedings,
      resolutions and authorizations have been or will be taken, passed, done
      and given to authorize, permit and enable it to execute and deliver this
      Agreement.

	 	 	 
	 	(d) 	
      The entering into of this Agreement will not be in
      contravention or constitute default under the laws of the incorporation
      jurisdiction of the Party or any indenture, deed, agreement, undertaking
      or obligation of the Party or to which it is a party.

	 	 	 
	 	(e) 	
      There are no actions or proceedings pending or, to its
      knowledge threatened which challenge the validity of this Agreement or
      which might result in a material adverse change in the financial condition
      of any Party or which would materially adversely
affect its ability to perform its obligations under this Agreement or
any other document in connection with them.








	 	(f) 	
      This Agreement is a valid, binding and enforceable
      obligation of each of the Parties in accordance with its terms.

	 	 	 
	 	(h) 	
      It has not, and to the best of its knowledge and
      following due inquiry, nor has any other Person, in relation to the
      Business received any notice of any breach of any Law or notice of default
      of any of the terms or provisions of any agreements or instruments in
      respect of the Business and it has no knowledge of any act or omission or
      any condition with respect to the Business which could be give rise to any
      such notice.

	 	 	 
	 	(i) 	
      None of the foregoing representations and warranties
      contains any untrue statement of a material fact or omits to state any
      material fact.



4.        
 FORMATION AND MANAGEMENT OF JOINT VENTURE COMPANY


4.01      On or before Closing,
NeutriSci and Lexaria shall form Newco as a corporation under the jurisdiction
of British Columbia. 

4.02      On or before Closing, the
Parties shall procure that such shareholder and director meetings are held, and
resolutions passed, to ensure that Newco shall have the characteristics set out
in this section. 

4.03      The authorized share capital
of Newco shall comprise of common shares without par value with each common
share entitling its holder to one vote. Upon incorporation, Newco shall have an
issued and outstanding of 50,000 common shares with NeutriSci and Lexaria each
holding 25,000 common shares of Newco. 

4.04      The name of Newco shall be
Ambari Corporation or any other name as mutually agreed to between the parties,
subject to the approval of the B.C. Registrar of Companies. 

4.05      Newco’s articles of
incorporation shall be substantially in the form in Schedule “A” attached
thereto. 

4.06      The registered office of
Newco shall be Suite 2200, HSBC Building 885 West Georgia Street, Vancouver,
B.C. V6C 3E8 upon or before Closing. 

4.07      The financial year-end of
the Newco shall end on December 31 in each year.

4.08      As soon as reasonably
practicable, Newco shall open USD and CAD bank accounts with the Board of
Directors having sole authority to approve all financial transactions in
connection with Newco and the Business.

4.09      Mr. Glen Rehman and Mr.
Chris Bunka shall each be appointed as directors (each a “Director”) ,
Mr. Keith Bushfield shall be appointed as the President (the
“President”), and Mr. John Docherty shall be appointed as Chief Technical
Officer (the “CTO”) of Newco.

4.10      The President shall be
responsible for the day-to-day operations of Newco and shall be employed on a
full-time basis with a monthly salary of CDN$12,500 per month (the
“President’s Salary”). Such salary shall be contributed by NeutriSci and Lexaria on a
monthly basis with NeutriSci contributing in the amount of CDN$10,000 per month
and Lexaria contributing in the amount of CDN$2,500 per month. 




4.11      On the earlier of six (6)
months from the Effective Date or in the event Newco completes an equity
financing (the “Equity Financing”) of no less than CND$500,000 on terms
subject to the unanimous consent of the Directors, then one-hundred percent
(100%) of the President’s Salary shall be paid by Newco.

4.12      Subject to the terms and
  provisions of this Agreement, the President shall have the following powers and
duties: 

	 	(a) 	
      The President shall manage, direct and control Operations
      with best efforts towards maximum efficiencies and
profitability;

	 	 	 
	 	(b) 	
      The President shall keep the Joint Venture Assets free
      and clear of all encumbrances, except for those existing at the time of,
      or created concurrently with, the acquisition of such Joint Venture
      Assets;

	 	 	 
	 	(c) 	
      The President shall obtain and maintain insurance for
      Newco, with such limits and deductibles, as would normally be maintained
      by a reasonably prudent manager in the circumstances;

	 	 	 
	 	(d) 	
      The President shall keep NeutriSci and Lexaria advised of
      all Operations by submitting in writing to each respective party a report
      every thirty (30) days. At all reasonable times the President shall
      provide NeutriSci and Lexaria access to, and the right to inspect, audit,
      and copy all production reports, invoices, operations and other
      information acquired in Operations; and

	 	 	 
	 	(e) 	
      The President shall conduct all Operations in a good,
      workmanlike and efficient manner, in substantial accordance with sound
      industry standards and practices.



4.13      In the event that six (6)
months from the Effective Data has passed and the Equity Financing has not been
completed, then the President’s Salary shall be reduced to CDN$5,000 per month
until such time as the CDN$500,000 financing has been completed. 

5.         
OPERATION OF JOINT VENTURE 

5.01      The Parties acknowledge that
any regulated substance such as cannabis oil is handled and transacted only by
local and state-licensed entities in all applicable jurisdictions. Evidence of
proper business insurance may be required.

5.02      After funds from the Initial
Contribution have been depleted, and before the completion of the Equity
Financing, subsequent funds required from time to time by the Parties to operate
the Business will be obtained first by funding as to 50% by Lexaria and 50% by
NeutriSci into the bank account of Newco. If a Party wishes to obtain a loan for
the Business to fund their required contribution to the Joint Venture, they
shall first provide the other Party with particulars of the terms of any such
proposed loan including the amount of any commitment or other loan fees, the
security required by the lender and other terms and conditions, and shall not
finalize any such loan without the prior written approval of the other Party,
such approval not to be unreasonably delayed or withheld. No Party may
encumber the Business nor offer the Business as security without the express
written permission of all other Parties to the Business. 




5.03      Commencing not sooner than
six (6) months following the Effective Date, the Net Profits as defined by
audited quarterly financial statements prepared under IFRS (or US GAAP) shall be
distributed to each of the Parties in proportion to their respective
then-current equity ownership interests on a quarterly basis in arrears, but
only after and the amount in excess of a net profit operating balance of
CDN$500,000 has been established. Then-current equity ownership interest shall
mean the lowest percentage equity ownership interest experienced by a Party at
any point in any Newco fiscal quarter. 

5.04      If either Party (the
"Defaulter") fails to provide its contribution to the Business within
twenty (20) business days from the date required (the "Deficiency"), then
the Party who has paid its contribution may give written notice to the Defaulter
to pay its Deficiency. If such Defaulter does not pay its Deficiency within
forty-five (45) days of such notice, that Party making its own contribution as
required (the "Contributor") will not be required to but may pay all or
any part of the Deficiency on behalf of the Defaulter. If the Contributor pays
all or any part of the Deficiency on behalf of the Defaulter: 

	 	(a) 	
      The total amount advanced by the Contributor on behalf of
      the Defaulter will be aggregated quarterly and interest will accrue on the
      same from the date or dates of such contribution at a rate of interest
      equal to that charged by the Bank of Canada’s prime rate plus 10 percent
      (10%). Such total amount and all interest accrued and unpaid thereon from
      time to time will be herein called the "Deficiency
Contribution";

	 	 	
       

	 	(b) 	
      Any Deficiency Contribution will be Payable by the
      Defaulter to the Contributor on demand (the “Demand Notice”) by the
      Contributor.

	 	 	
       

	 	(c) 	
      Any Deficiency Contribution payment that has been
      demanded and not paid within 30 days of such demand notice shall be
      immediately, and without further notice by the Contributor, convertible at
      the exclusive option of the Contributor into 1% of ownership interest of
      Newco for every CDN$10,000 of the Deficiency Contribution including unpaid
      interest. The Defaulter in this case agrees to enter a purchase and sale
      agreement with the Contributor 30 days following the Demand Notice that
      will effect the sale of Defaulter’s ownership interest in Newco to
      Contributor at the rate of 1% of ownership for every CDN$10,000 of
      Deficiency Contribution paid by Contributor, including unpaid
    interest.



5.05      The President shall present
to the Directors for review and approval a one-year business plan and one-year
budget within fourty-five (45) days of the Effective Date. The business plan
will include the normal items found within a business plan, including but not
limited to: executive summary; budgets; financing plans; revenue forecasts;
operations; management and operations structure; key products and services;
market for key products and services; and sales, distribution and marketing
strategies, etc. 

5.06      The
President shall present to the Directors on not less than a monthly basis,
management and operations meetings to inform the Directors fully on all aspects
of the previous month’s Operations of the Business of Newco, and to discuss and
plan for the Operations of the Business of Newco for the month to come. The
President shall prepare and circulate minutes of each meeting to the Directors
not more than seven (7) days after each meeting is held. Meetings will generally
be held by teleconference but can also be conducted in-person. Any of the
Directors and the President can call a meeting at any time with five (5)
business-days’ notice to the other participants. A meeting is not valid unless a
quorum is present, and a quorum is defined as not less thanthree eligible
persons from the then-current list of Directors and President and Chief
Technology Officer. 




5.07      The President shall be
responsible for obtaining and managing appropriate liability insurance for the
purposes of; ensuring all monthly accounts with 3rd party vendors are
kept up to date; to apply for all necessary permits, licenses and similar
authorizations in the conduct of the Business; and to notify the Directors in
writing of any allegations or reasonable suspicion of fraud, illegal activities
or non-compliance with any bylaws or other regulations. 

5.08      It is understood by the
Parties that the Business of NewCo shall include development and
commercialization of products that may contain controlled substances derived
from marijuana and/or hemp in certain jurisdictions, e.g., cannabidiol and/or
tetrahydrocannabinol. The President shall be responsible for ensuring that all
developmental and finished products produced and hereunder are handled, tested,
distributed and/or sold in compliance with all laws applicable to the
cannabinoid industry within the relevant jurisdiction(s). In order to do so, it
is further understood by the Parties that the President may, from time to time,
be required to contract the services of appropriately licensed, third party
manufacturers, testing facilities and distributors. When necessary, the
President will endeavor to do so with the best financial terms, respecting all
provisions outlined in Sections 6 and 10 hereunder and with the understanding
that he is not permitted to sublicense any intellectual property to any third
party without the express written mutual consent of the Directors.

6.         
INTELLECTUAL PROPERTY 

6.01      Lexaria retains full,
absolute, and complete rights to all processes covered or described in all of
its granted and/or pending patent applications filed prior to and following the
date of this Agreement, and any future continuations, continuations in part or
divisional applications filed thereto comprise its technology in addition to any
unpatented trade secrets, know-how or formulations not generally available to
the public as shown in Schedule “B” attached hereto (“Lexaria IP”) and
reserves the right to license or otherwise utilize such Lexaria IP for any
purpose whatsoever. 

6.02      NeutriSci retains full,
absolute, and complete rights to all processes covered or described in all of
its granted and/or pending patent applications filed prior to and following the
date of this Agreement, and any future continuations, continuations in part or
divisional applications filed thereto comprise its technology, in addition to
any unpatented trade secrets, know-how or formulations not generally available
to the public as shown in Schedule “C” attached hereto (“NeutriSci IP”)
and reserves the right to license or otherwise ulitlize such NeutriSci IP for
any purpose whatsoever. 

6.03      Any intellectual property
resulting from NeutriSci or its parent company’s work, know-how, or development
that does not include or rely upon Lexaria’s IP, or from jointly owned
intellectual property, shall be owned by NeutriSci or its parent company
(“NeutriSci New IP”). 

6.04      Any intellectual property
resulting from Lexaria’s or its subsidiary Lexaria CanPharm Corp’s work,
know-how, or development that does not include or rely upon NeutriSci’s IP or
from jointly owned intellectual property, shall be owned by Lexaria or by
Lexaria CanPharm Corp (“Lexaria New IP”). 

6.05      Joint Improvements: Rights
and title to intellectual property improvements made by either party, whether or
not patentable, and any patent applications or patents based thereon, which
directly relate to and are not severable from either party’s intellectual
property shall be jointly owned intellectual property (“Jointly Owned
IP”) by both Parties under an exclusive, non-sub-licensable, fully-paid,
royalty-free, perpetual license. The Parties shall cooperate to cause the filing
of one or more patent applications covering any such Jointly Owned IP. The
Parties will mutually agree upon which of them shall be responsible for filing, prosecution and maintenance of Jointly Owned IP. The
expenses of such filing, prosecution and maintenance shall be equally shared by
the Parties unless one of the Parties assigns all of its rights to the other
Party. Both Parties agree to assist the other Party in enforcing its rights in
the Jointly Owned IP. The costs of any such assistance or cooperation will be
borne by the requesting party.




6.06      Rights and title to
intellectual property improvements after the execution of the Agreement which
are conducted, researched, discovered by Newco and/or Lexaria and/or NeutriSci,
relating to the Business, products of Newco, its employees and consultants
whether or not patentable, and any patent applications or patents based thereon,
which directly relate to and are not severable from NeutriSci IP, NeutriSci New
IP, Lexaria IP, or Lexaria New IP and which are improvements thereto by Newco,
its employees or its partners, shall be owned by Newco (“Newco
Improvements”). In respect to such Newco Improvements, Newco shall grant to
each of the Parties a license to use the underlying intellectual property
supporting any such improvement for the term the Agreement (including any
renewal terms) and Newco shall agree to negotiate in good faith terms of license
renewal after the end of the term of the Agreement.

6.07      If Lexaria or NeutriSci
  develops any Newco Improvements, then Lexaria or NeutriSci will promptly provide
  Newco with written notice of such improvements. Following receipt of notice of
  such improvements, each of the Parties shall have the exclusive right during the
  term of the Agreement to receive a license from Newco for the improvements for
  that party’s use (not to be re-licensed to third parties). After the Agreement
  expires, each Party shall have the option, upon mutually agreeable terms and
  conditions that the Parties shall negotiate in good faith, to license the
  improvements for its own use but not to be re-licensed to third parties, though
  nothing shall be interpreted to require Newco to sell or license the
improvements to either party after the License Agreement expires. 

6.08      The Parties shall represent
that all partners, employees and other persons acting on its behalf in
performing their obligations shall be obligated under a binding written
agreement to assign, or as they each shall direct, all intellectual property
improvements that include or rely on intellectual property conceived or reduced
to practice by such partners, employees or other persons acting on their behalf
in accordance with this Agreement. 

6.09      Upon making any invention
that does not include or rely upon Jointly Owned IP, Newco Improvements or upon
intellectual property belonging to the other party, the discovering party has no
obligation to share such information of invention with the other party nor
inform Newco of said invention, and the discovering party retains unrestricted
rights and ability to use, assign, license, seek patent and other forms of
intellectual property protection related to said invention.

6.10      Upon execution of this
Agreement, the Parties each agree to license its respective or jointly owned
intellectual property, know-how and processes to Newco at no charge to the
extent Newco requires in order to execute its business plan. 

7.         
DEFAULT 

7.01      It is an event of default (a
"Default") if a Party (the "Defaulting Party", the other Parties
being the "Non-Defaulting Parties"): 

	 	(a) 	
      fails to observe, perform or carry out any of his
      obligations hereunder and such failure continues for thirty (30) days
      after any of the Non-Defaulting Parties have, in writing, demanded that
      such failure be cured;








	 	(b) 	
      fails to take reasonable actions to prevent or defend
      assiduously any action or proceeding in relation to any of their Ownership
      Interest for seizure, execution or attachment or which
  claims:




	 	(i) 	
      possession;

	 	 	 
	 	(ii) 	
      sale;

	 	 	 
	 	(iii) 	
      the appointment of a receiver or receiver-manager of its
      assets; or

	 	 	 
	 	(iv) 	
      forfeiture or termination;




	 		
      of or against any of the Ownership Interest of the
      Defaulting Party, and such failure continues for thirty (30) days after a
      Non-Defaulting Party has, in writing, demanded that the same be taken or
      the Defaulting Party fails to defend successfully any such action or
      proceeding;

	 	 	 
	 	(c) 	
      becomes bankrupt or commits an act of bankruptcy or if a
      receiver or receiver-manager of his assets is appointed or makes an
      assignment for the benefit of creditors or otherwise;

	 	 	 
	 	(d) 	
      fails after fourteen days' notice in writing to the other
      to resolve any deficiency or breach of Section 5.04 or of Section 11,
      hereof.



7.02      In the event of a Default,
the Non-Defaulting Parties may do any one or more of the following: 

	 	(a) 	
      pursue any remedy available to them in law or in equity,
      it being acknowledged by each of the Parties that specific performance,
      injunctive relief (mandatory or otherwise) or other equitable relief may
      be the only adequate remedy for a Default;

	 	 	 
	 	(b) 	
      take all actions in their own names or in the name of the
      Defaulting Party or the Parties as may reasonably be required to cure the
      Default, in which event all payments, costs and expenses incurred therefor
      shall be payable by the Defaulting Party to the Non-Defaulting Parties on
      demand with interest at the Royal Bank of Canada prime commercial rate of
      interest for its most creditworthy customers plus 6% per annum;

	 	 	 
	 	(c) 	
      implement the ownership valuation sales procedure as set
      out in Section 5.04 hereof;

	 	 	 
	 	(d) 	
      waive the Default provided, however, that any waiver of a
      particular Default shall not operate as a waiver of any subsequent or
      continuing Default.



8.         
NO PARTNERSHIP 

8.01      Except as otherwise
expressed in this Agreement, the rights and obligations of the Parties will be,
in each case, several, and will not be or be construed to be either joint or
joint and several. Nothing contained in this Agreement will, except to the
extent specifically authorized hereunder, be deemed to constitute a Party a
partner, an agent or legal representative of the other Parties. It is intended
that this Agreement will not create the relationship of a partnership among the
Parties and that no act done by any Party pursuant to the provisions hereof will operate to create
such a relationship. 




8.02      Notwithstanding Section
8.01, in the event the Parties wish to enter into a partnership, they may do so
with an additional addendum to this Agreement.

9.         
FINANCIAL 

9.01      Each Party shall be
responsible for and pay their own respective corporate and personal tax and duty
obligations, whether in Canada, the United States, or elsewhere, and each of the
Parties shall hold the other and the Joint Venture harmless and agree to
indemnify them for those tax and duty obligations, as well as and costs of
collection, interest, fines, penalties, or litigation. 

9.02      The books of account of the
Business shall be maintained on an accrual basis in accordance with
International Financial Reporting Standards, consistently applied, and shall
show all items of income and expense, all assets and liabilities and the
contribution accounts of the Parties. 

9.03      Any Party shall have the
right from time to time at all reasonable times during usual business hours and
without causing a material disruption of the Business, to audit, examine and
make copies of or extracts from all records relating to the Business. Such right
may be exercised through any agent or employee of such Party designated by it,
or by independent accountants designated by such Party. Such Party shall bear
all expenses incurred in any such audit or examination or for copies or extracts
made at such Party's request. 

9.04      Any combination of the CFO,
controller, and/or auditors of each of the Parties shall have online read-only
access to Newco’s bank account for purposes of auditing and accounting. Newco
shall provide to each of the Parties, within 15 days of each Party’s fiscal
quarter-end, financial statements detailing the financial operations and
performance for the 3-month period just ended, and simultaneously provide copies
of all Newco bank statements, expense reports, and material agreements for the
3-month period just ended. Computerized records shall be kept in SAGE or
equivalent software and be made available to either Party’s financial personnel
as described within this Section within two (2) business day’s notice. 

9.05      Unanimous written consent in
advance from the Directors is required in each of these circumstances: 

	 	i) 	
      Aggregate funding schedules or budgets for all aspects of
      building, growing and operating the Business that involve annual budgets
      of CDN$100,000 or more;

	 	 	 
	 	ii) 	
      Each capital expenditure incurred by the Business or
      Operations of more than CDN$75,000 and each salary, wage or bonus offered
      by the Business or Operations of more than CDN$75,000 per annum; or salary
      wage or bonuses paid to the same party, or capital expenditures paid to
      the same supplier or service provider that in aggregate exceed CDN$75,000
      per annum.

	 	 	 
	 	iii) 	
      Sales or marketing deals or alliances which involve
      costs, discounts or concessions greater than CDN$25,000 in any given
      year








	10. 	
      CONFIDENTIALITY

	 	 
	10.01 	
      Confidential Information - In this Agreement,
      references to a “Disclosing Party” mean a party disclosing Confidential
      Information, and references to a “Receiving Party” mean a party receiving
      Confidential Information.

	 	 
	10.02 	
      In this Agreement, the term “Confidential Information”
      means the following disclosed, generated or derived in connection with the
      Business (a) any information of whatever nature or form relating to the
      Disclosing Party and its affiliates, subsidiaries, or any customer of or
      supplier or lender of the Disclosing Party and its affiliates regardless
      of whether the Confidential Information was communicated orally, in
      writing or by electronic transmission, and (b) any summaries, notes,
      analyses, compilations, studies or other records that contain or otherwise
      reflect or have been generated, wholly or partly, or derived from such
      Confidential Information (“Derivative Information”). The term
      “Confidential Information” shall not include such portions of the
      Confidential Information which (i) are, or prior to the time of disclosure
      or utilization become, generally available to the public other than as a
      result of a disclosure by the Receiving Party or its Representatives (as
      hereafter defined), or (ii) are received by the Receiving Party from an
      independent third party who had obtained the Confidential Information
      lawfully and to its knowledge was not under an obligation of secrecy or
      duty of confidentiality owed to the Disclosing Party, or (iii) the
      Receiving Party can show were in its lawful possession before it received
      such Confidential Information from the Disclosing Party, or (iv) the
      Receiving Party can show was independently developed by the Receiving
      Party or on the Receiving Party’s behalf.

	 	 
	10.03 	
      Non-Disclosure and Restricted Use − The
      Confidential Information will be kept confidential and will not, without
      prior written consent of the Disclosing Party, or as expressly provided in
      this Agreement, be disclosed by the Receiving Party in any manner
      whatsoever, in whole or in part, and will not be used by the Receiving
      Party, directly or indirectly, for any purpose other than evaluating and
      completing the Business.

	 	 
	10.04 	
      Storage and Records – The Receiving Party shall
      store the Confidential Information properly and securely and ensure that
      reasonable physical, technological and organisational measures are in
      place to protect the Confidential Information against unauthorised or
      unintended access, use or disclosure.

	 	 
	10.05 	
      Access Limited to Representatives – The Receiving
      Party may reveal or permit access to the Confidential Information only to
      its subsidiaries or parent company, agents, representatives (including
      lawyers, accountants and financial advisors), directors, officers and
      employees (each a “Representative”) who need to know the
      Confidential Information for the Business, who are informed by the
      Receiving Party of the confidential nature of the Confidential
      Information, who are directed by the Receiving Party to hold the
      Confidential Information in confidence and who agree to act in accordance
      with the terms and conditions of this Agreement. The Receiving Party will
      take all necessary precautions or measures to prevent improper access to
      the Confidential Information or use or disclosure of the Confidential
      Information by its Representatives and will be responsible for any breach
      of this Agreement by any of its Representatives. The Receiving Party will,
      in the event of a breach of the Agreement or any disclosure of
      Confidential Information by the Receiving Party or its Representatives,
      other than as permitted by this Agreement, through accident, inadvertence,
      or otherwise, notify the Disclosing Party of the nature of the breach
      promptly upon the Receiving Party’s discovery of the
  breach.








	10.06 	
      Proprietary Rights - The Receiving Party
      acknowledges that the Confidential Information is a proprietary asset of
      the Disclosing Party and its affiliates and agrees that as between the
      Receiving Party and the Disclosing Party, the Disclosing Party will retain
      proprietary rights in the Confidential Information and the disclosure of
      such Confidential Information shall not be deemed to confer upon the
      Receiving Party any rights whatsoever in respect of any Confidential
      Information. 

	  	
       

	10.07 	
      Return of Confidential Information - Upon the
      request of the Disclosing Party, the Receiving Party and its
      Representatives will, at the Receiving Party’s own expense, promptly
      return all copies of the Confidential Information, except for that portion
      of the Confidential Information which consists of Derivative Information
      which will be destroyed and in the case of information stored in
      electronic form, it will be permanently erased. Notwithstanding the return
      or destruction of the Confidential Information, the Receiving Party and
      its Representatives shall continue to be bound by the confidentiality and
      other obligations hereunder. 

	  	
       

	10.08 	
      No Representation – Although the Disclosing Party
      will endeavour to include in the Confidential Information data which the
      Disclosing Party believes to be reliable and relevant for the purpose of
      evaluating the Business, the Receiving Party acknowledges that the
      Disclosing Party makes no representation or warranty as to the accuracy or
      completeness of the Confidential Information. The Receiving Party also
      agrees that neither the Disclosing Party nor its Representatives shall
      have any liability, direct or indirect, to the Receiving Party as a result
      of errors in, omissions from or the use of Confidential Information by the
      Receiving Party or its Representatives. 

	  	
       

	10.09 	
      Required Disclosure − In the event that the
      Receiving Party or any of its Representatives become legally compelled or
      are required by regulatory authorities having appropriate jurisdiction to
      disclose any of the Confidential Information, the Receiving Party will
      promptly provide the Disclosing Party with written notice so that the
      Disclosing Party may seek a protective order or other appropriate remedy
      and/or waive compliance with the provisions of this Agreement. The
      Receiving Party will cooperate with the Disclosing Party on a commercially
      reasonable basis to obtain a protective order or other remedy. In the
      event that such protective order or other remedy is not obtained before
      the Receiving Party or its Representatives become compelled or required to
      disclose as aforesaid, or the Disclosing Party waives compliance with the
      provisions of this Agreement, the Receiving Party will furnish only that
      portion of the Confidential Information which is legally required to be
      disclosed and will exercise all commercially reasonable efforts to obtain
      reasonable assurance that confidential treatment will be accorded the
      Confidential Information so furnished. 

	  	
       

	10.10 	
      Acknowledgement – The Parties acknowledge that
      access by it or its Representatives to the confidential information may
      provide such party with material confidential information concerning Newco
      or either of the Parties or its affiliates which has not been publicly
      disclosed. Accordingly, each party may be subject to applicable securities
      laws, including the securities laws in Canada and the USA, which would
      restrict its ability to trade in any of either the Parties’ or any of its
      affiliates, subsidiaries’ and parent company’s securities. This agreement
      does not represent a commitment on the part of either party hereto to
      purchase the products or services of the other party nor a commitment to
      enter into any business venture with the other party nor an encouragement
      to expend funds in the development of any products or services. Further,
      this agreement does not in any way prevent or constrain either party’s use
      of any other provider of, or either party’s current or future development
      of, products or services similar to the products or services provided by
      the other party hereto or the products or services which are the subject
      of the discussions anticipated by this agreement.









	10.11 	
      Certain Definitions − In this Agreement, the term
      “affiliate” shall mean a person directly or indirectly controlling, or
      controlled by, or under common control with, the Receiving Party or the
      Disclosing Party, as the case may be, with “control” meaning the
      possession, directly or indirectly or as trustee or executor, of the power
      to direct or cause the direction of the affairs or management of a person,
      whether through the ownership of voting securities, as trustee or
      executor, by contract or otherwise. The term “person” shall mean an
      individual, corporation, partnership, limited partnership, limited
      liability company, joint venture, estate, association, trust,
      unincorporated organization, or other entity of any kind or
  nature.

	 	 
	12. 	
      Governing Law − This Agreement shall be governed
      by and construed in accordance with the laws of the Province of British
      Columbia and the federal laws of Canada applicable in the Province of
      British Columbia.

	 	 
	13. 	
      Non-Waiver − No failure or delay by either party,
      as the case may be, in exercising any right, power or privilege under this
      Agreement will operate as a waiver thereof unless such right, power or
      privilege expires by the terms of this Agreement, nor will any single or
      partial exercise preclude any other or further exercise of any right,
      power or privilege under this Agreement.

	 	 
	14. 	
      Injunctive Relief − The parties acknowledge that
      disclosure of the Confidential Information or other breach of this
      Agreement would cause serious and irreparable damage and harm, and that
      remedies at law would be inadequate to protect against breach of this
      Agreement, and agree in advance to the granting of injunctive relief in
      each other’s favour for any breach of the provisions of this Agreement and
      to the specific enforcement of the terms of this Agreement, without proof
      of actual damages, and without the requirement to post a bond or other
      security, in addition to any other remedy to which the parties would be
      entitled.

	 	 
	15. 	
      Term − The parties acknowledge that the
      confidentiality and non-use obligations in this Agreement pertaining to
      Confidential Information shall persist for so long as this Agreement is in
      effect, and also survive any termination or expiration of this Agreement
      for a period of two (2) years after disclosure by the Disclosing Party to
      the Receiving Party.

	 	 
	11. 	
      BUY-SELL PROCEDURE

	 	 
	11.01 	
      If either of the Parties is desirous of selling all or
      any part of its Ownership Interest in Newco (the “Selling Party”),
      then it must first offer such Ownership Interest to the other Party before
      offering such Ownership Interest to any third party. The Selling Party
      (hereinafter referred to as the "Offeror") shall give to the other
      party (hereinafter referred to as the "Offeree") notice in writing
      which shall contain the following terms and
provisions:




	 	(a) 	
      the price for the Ownership Interest to be
sold;

	 	 	 
	 	(b) 	
      an offer to buy all of the Ownership Interest owned by
      the Offeree at a fixed price per percentage point of ownership (the
      “Sale Price”) determined solely by the Offeror;

	 	 	 
	 	(c) 	
      an offer to sell all of the Ownership Interest owned by
      the Offeror to the Offeree at the same Sale Price determined solely by the
      Offeror; and

	 	 	 
	 	(d) 	
      payment of an amount equal to the total purchase price by
      certified cheque or any other valuable consideration agreeable to both
      Parties on closing.








	11.02 	
      Upon receipt of the notice, the Offeree may, within a
      period of 30 days thereafter, accept either one of the offers contained in
      the notice and shall give written notification to the Offeror accepting
      either the Offeror's offer to purchase or the Offeror's offer to sell as
      contained in the notice.

	 	 
	11.03 	
      The individual parties hereto agree that failure to
      accept within the time limited as aforesaid shall be for all intent and
      purposes be deemed to have been a rejection of the Offeror's offer to
      purchase in the same manner as if the Offeree had, in fact, rejected such
      offer to purchase by notice in writing. The appropriate offer in
      accordance with the foregoing and acceptance thereof by either notice in
      writing or the failure of the Offeree to accept the same shall be deemed
      to constitute a binding agreement of purchase and sale as set out in the
      Offeror's notice and in the terms and provisions of this Agreement. The
      transaction or transactions of purchase and sale arising from the
      foregoing shall be completed within 60 days after acceptance.

	 	 
	11.04 	
      In the event of a sale of an Ownership Interest in Newco
      as herein provided for, the party selling shall in this Section be
      referred to as the "Seller" and the party purchasing shall in this
      Section be referred to as the "Purchaser", and the following
      additional provisions shall apply:




	 	(a) 	
      the date scheduled for closing (the “Sale of Ownership
      Closing") may be at any earlier date agreed to and fixed by the
      individual parties hereto;

	 	 	 
	 	(b) 	
      any amount payable under the agreement of purchase and
      sale or other agreed transaction shall be paid by of certified cheque or
      as otherwise acceptable to both Parties;

	 	 	 
	 	(c) 	
      if, upon the date set for the Sale of Ownership Closing,
      the Parties shall be indebted to the Seller in an amount recorded on the
      books of the Parties and verified by the auditors/accountants of the
      Parties, such indebtedness shall be paid to the Seller by the Parties at
      the time of the Sale of Ownership Closing;

	 	 	 
	 	(d) 	
      if, upon the date set for the Sale of Ownership Closing,
      the Seller shall be indebted to the Parties in an amount so recorded and
      verified, the Purchaser shall be entitled under the purchase price to pay,
      satisfy and discharge all or any portion of such indebtedness and to
      receive and to take credit against the purchase for the amount or amounts
      so paid on account of such indebtedness;

	 	 	 
	 	(e) 	
      if, on the date of the Sale of Ownership Closing, the
      Seller is responsible on any covenant for the liabilities of Business the
      Purchaser shall procure for the Seller and deliver at the time of closing
      releases from any such covenants or guarantees or, failing that, shall
      indemnify the Seller from any claim, action, demand or liability that may
      arise by reason of such covenants or guarantees;

	 	 	 
	 	(f) 	
      if, on the date of the Sale of Ownership Closing, the
      Seller shall have any securities lodged with any person, including the
      Parties' bankers, to secure any indebtedness of the Parties, then the
      Purchaser shall deliver the same free and clear of any claims in
      connection with such indebtedness to the Seller. In the event the
      Purchaser is unable to deliver the same, then the Purchaser shall execute
      all such documents as may be reasonably required in order to indemnify and
      save harmless the Seller in relation thereto;

	 	 	 
	 	(g) 	
      if, on the date of the Sale of Ownership Closing, the
      Seller shall, for any reason, fail or refuse to complete the transaction, the Purchaser shall have
the right upon such default without prejudice to any other rights which the
Purchaser may have, upon payment by the Purchaser of the balance due on closing
(less or plus any adjustment herein permitted) to the credit of the Seller in
any chartered bank in the Province of British Columbia or the solicitors for the
Business on behalf of and in the name of the Seller to complete the transaction
as aforesaid and the Seller hereby irrevocably constitutes the Purchaser the
true and lawful attorney of the Seller to complete the transaction and to
execute any and every document necessary in that behalf; 








	 	(h) 	
      between the date of any offer and the date of the Sale of
      Ownership Closing of any ensuing transaction neither the Seller nor the
      Purchaser shall do or cause to be done anything except in the ordinary
      course of business;

	 	 	 
	 	(i) 	
      notwithstanding any term or provision of this Agreement
      to the contrary, once any of the sale provisions hereinbefore referred to
      are invoked or become operative pursuant to the provisions of this
      Agreement, no other offer or notice of sale or intention to sell shall be
      given or accepted until the Sale of Ownership Closing or termination of
      the ensuing transaction.




	11.05 	
      In the event that no transaction is completed via the
      provisions of Sections 11.01 through 11.04, above, then the Selling Party
      is permitted to offer all or any part of its Ownership Interest to any
      third party. In the event that the Selling Party reaches any agreement,
      letter of intent or similar to sell all or any part of its Ownership
      Interests (the “Intent to Purchase”), AND in the event that any
      price, term, or condition of such Intent to Purchase differs from the
      offer may under Section 11.01, above, then all the provisions of Sections
      11.01 through 11.04 must be offered by the Selling Party to the Offeree
      PRIOR to the Selling Party completing its proposed sale transaction with
      the third party.

	 	 
	12. 	
      GENERAL PROVISIONS

	 	 
	12.01 	
      This Agreement shall
terminate:




	 	(a) 	
      The Parties, acting together, collectively sell the
      Business after which this Agreement will cease to have any effect or be
      binding upon the parties except in respect of the resolution of the rights
      and obligations of the parties during the period prior to such sale and
      the payment of all monies between the parties arising as a result;
    or

	 	 	 
	 	(b) 	
      if the Parties hereto consent in writing to the
      termination hereof.



12.02      NeutriSci and Lexaria shall
execute such further assurances and other documents and instruments and do such
further and other things as may be necessary to implement and carry out the
intent of this Agreement. 

12.03      The provisions herein
constitute the entire agreement between the Parties and supersedes all previous
expectations, understandings, communications, representations and agreements,
whether verbal or written, including the MOU, between the Parties with respect
to the subject matter hereof. 

12.04      If any provision of this
Agreement is unenforceable or invalid for any reason whatever, it shall not
affect the enforceability or validity of the remaining provisions of this
Agreement and such provision shall be severable from the remainder of this Agreement. 




12.05      Any notice required to be
given hereunder by any party shall be deemed to have been well and sufficiently
given if mailed by prepaid registered mail return receipt requested, courier
service or by electronic communication, capable of producing a printed
transmission to or delivered at the address of the other party first written
above or at such other address as any of the parties may from time to time
direct in writing, and any such notice shall be deemed to have been received, if
mailed or couriered, forty-eight hours after the time of mailing or if sent by
electronic communication on the date of such communication. If normal mail
service or courier service is interrupted by strike, slow down, force majeure or
other cause, a notice sent by the impaired means of communication will not be
deemed to be received until actually received, and the party sending the notice
shall utilize any other such services which have not been so interrupted or
shall deliver such notice in order to ensure prompt receipt thereof. 

12.06      Time shall be of the
essence hereof. 

12.07      This Agreement shall be
governed by and construed in accordance with the laws in force in the Province
of British Columbia from time to time. 

12.08      Each of NeutriSci and
Lexaria shall make, do and execute or cause to be made, done or executed all
such further things, acts, documents, conveyances and assurances as may be
necessary or reasonably required to carry out the intent and purpose of this
Agreement fully and effectually. 

12.09      This Agreement shall enure
to the benefit of and be binding upon the Parties and their respective personal
representatives, successors and permitted assigns. 

12.10      This Agreement may be
signed by facsimile, email, or original, and executed in any number of
counterparts, and each executed counterpart will be considered to be an
original. All executed counterparts taken together will constitute one
agreement 

-Signature Page Follows- 




IN WITNESS WHEREOF the parties have executed this
Agreement as of the day and year first above written. 

	NEUTRISCI INTERNATIONAL CORP. 	 
	 	 
	 	 
	Per:		 
	Authorized Signatory 	 
	 	 
	 	 
	 	 
	LEXARIA BIOSCIENCE CORP. 	 
	 	 
	 	 
	Per:		 
	Authorized Signatory 	 






SCHEDULE "A" 

Form of Articles of Newco 




SCHEDULE "B" 

List of Lexaria IP and Knowhow

Lexaria Owned Trademarks: 


	  	Application 	  	  
	TurboTHC 	1822307 	Feb 10, 2017 	USA#87256120 
	TurboCBD 	1822307 	Feb 10, 2017 	USA#87142224 
	ViPova 	Pending.... 	  	  



Lexaria Patent Information: 

		 	Application 	Application Filing 	Attorney Docket 	Issued 	Issuance 
	No. 	Application# 	Type 	Date 	# 	Patent# 	Date 
	 	 	US 	 	 	 	 
	1 	62/010,601 	Provisional 	06/11/2014 	007341-001PV1 	 	 
	 	 	US 	 	 	 	 
	2 	62/037,706 	Provisional 	08-15-2014 	007341-001PV2 	 	 
	 	 	US 	 	 	 	 
	3 	62/153,835 	Provisional 	04-28-2015 	007341-001PV3 	 	 
	 	 	US 	 	 	 	 
	4 	62/161,324 	Provisional 	05-14-2015 	007341-001PV4 	 	 
	5 	14/735,844 	US Utility 	06/10/2015 	007341-001US1 	9,474,725 	10-25-2016 
	 	 	US 	 	 	 	 
	6 	15/225,799 	Continuation 	08/01/2016 	007341-001US2 	 	 
	 	 	US 	 	 	 	 
	7 	15/225,802 	Continuation 	08/01/2016 	007341-001US3 	 	 
	 	 	PCT 	 	 	 	 
	8 	PCT/US15/35128 	International 	06/10/2015 	007341-001WO1 	 	 
	 	 	Australia 	 	 	 	 
	9 	2015274698 	National 	06/10/2015 	007341-001AU1 	Pending 	06/02/2017 
	 	 	Australia 	 	 	 	 
	10 	To Be Filed 	Divisional 	06/10/2015 	007341-001AU2 	 	 
	 	 	Canada 	 	 	 	 
	11 	2949369 	National 	06/10/2015 	007341-001CA1 	 	 
	 	 	China 	 	 	 	 
	12 	201580031524.X 	National 	06/10/2015 	007341-001CN1 	 	 







	 	 	Europe 	 	 	 	 
	13 	15806768.6 	National 	06/10/2015 	007341-001EP1 	 	 
	 	 	India 	 	 	 	 
	14 	201647041745.00 	National 	06/10/2015 	007341-001IN1 	 	 
	 	 	Japan 	 	 	 	 
	15 	516371405 	National 	06/10/2015 	007341-001JP1 	 	 
	 	 	US 	 	 	 	 
	16 	62/264,959 	Provisional 	12/09/2015 	007341-002PV1 	 	 
	 	 	PCT 	 	 	 	 
	17 	PCT/US16/64295 	International 	12/01/2016 	007341-002WO1 	 	 
	 	 	US 	 	 	 	 
	18 	62/264,967 	Provisional 	12/09/2015 	007341-003PV1 	 	 
	 	 	PCT 	 	 	 	 
	19 	PCT/US16/64296 	International 	12/01/2016 	007341-003WO1 	 	 
	 	 	US 	 	 	 	 
	20 	In Preparation 	Provisional 	 	007341-004PV1 	 	 






SCHEDULE "C" 

List of Neutrisci IP and Knowhow 

Pteropure: 

	 	- 	Pterostilbene Patents - List of numbers
  



	 	o 	8,133,917 
	 	o 	8,252,845 
	 	o 	USSN 12/136,341 (US 2009/0069444 A1) 
	 	o 	PCT/IN2009/000313 (WO 2010/010578 A2) 
	 	o 	USSN 13/105,470 
	 	o 	US 61/484,977 
	 	o 	US 61/535,143 
	 	o 	US 61/570,048 



	 	- 	International Filing and Issued Patents 
	 	  	PCT 
	 	  	PCT/US2012/064933 
	 	  	Korea 
	 	  	10-2012-7013257 
	 	  	Mexico 
	 	  	2012/005013 
	 	  	Russia 
	 	  	2012 122241 
	 	  	EU 
	 	  	5774387.4 
	 	  	10775793.2 
	 	  	Canada 
	 	  	2778151 
	 	  	China 
	 	  	201080048865.5 
	 	  	Israel 
	 	  	219318 
	 	  	Japan 
	 	  	2012-535862 


Purenergy: 

	 	- 	Purenergy Patents – List of Numbers
  



	 	o 	8,399,712 


Nicotinamide Riboside (NR): 

	 	- 	NR Patents – List of Numbers




	 	o 	8,106,184 
	 	o 	8,114,626 







	 	o 	8.197,807 
	 	o 	8,383,086 
	 	o 	7,776,326 


Trademarks: 

	 	- 	Canadian Trademarks – List of Numbers
  



	 	o 	TMA961,065 
	 	o 	TMA961,066 
	 	o 	TMA942,093 
	 	o 	TMA950,267 
	 	o 	TMA942,104 
	 	o 	TMA941,719 



	 	- 	United States Trademarks – List of Numbers
  



	 	o 	5,067,059 


Industrial Design: 

	 	- 	Industrial Design – List of Numbers
  



	 	o 	164890